{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T14:52:53Z","timestamp":1790952773675,"version":"4.1.0"},"reference-count":58,"publisher":"Society of Nuclear Medicine","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"accepted":{"date-parts":[[2025,7,29]]},"published-print":{"date-parts":[[2025,10]]},"DOI":"10.2967\/jnumed.125.270317","type":"journal-article","created":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T16:35:18Z","timestamp":1756398918000},"page":"1522-1527","source":"Crossref","is-referenced-by-count":11,"title":["Combining PSMA-Targeted Radiopharmaceutical Therapy with Immunotherapy"],"prefix":"10.2967","volume":"66","author":[{"given":"Bet\u00fcl","family":"Altunay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Sch\u00e4fer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Morgenroth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quim","family":"Pe\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Twan","family":"Lammers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Saar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix M.","family":"Mottaghy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"L\u00fctje","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2025,8,28]]},"reference":[{"key":"2025100106250821000_66.10.1522.1","doi-asserted-by":"publisher","DOI":"10.3322\/CAAC.21834"},{"key":"2025100106250821000_66.10.1522.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00237-3"},{"key":"2025100106250821000_66.10.1522.3","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/S0140-6736(24)01653-2","article-title":"Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial","volume":"404","author":"Morris","year":"2024","journal-title":"Lancet."},{"key":"2025100106250821000_66.10.1522.4","first-page":"1441","article-title":"Alternatively spliced variants of prostate-specific membrane antigen RNA: ratio of expression as a potential measurement of progression","volume":"55","author":"Su","year":"1995","journal-title":"Cancer Res."},{"key":"2025100106250821000_66.10.1522.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2019.06.030"},{"key":"2025100106250821000_66.10.1522.6","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-023-06255-8"},{"key":"2025100106250821000_66.10.1522.7","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3239"},{"key":"2025100106250821000_66.10.1522.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA2407417"},{"key":"2025100106250821000_66.10.1522.9","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70189-5"},{"key":"2025100106250821000_66.10.1522.10","doi-asserted-by":"crossref","first-page":"E498","DOI":"10.1016\/S1470-2045(15)00007-8","article-title":"Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy","volume":"16","author":"Sharabi","year":"2015","journal-title":"Lancet Oncol."},{"key":"2025100106250821000_66.10.1522.11","doi-asserted-by":"publisher","DOI":"10.4161\/onci.28518"},{"key":"2025100106250821000_66.10.1522.12","doi-asserted-by":"crossref","first-page":"505","DOI":"10.3389\/fimmu.2015.00505","article-title":"Radio-immunotherapy-induced immunogenic cancer cells as basis for induction of systemic anti-tumor immune responses\u2014pre-clinical evidence and ongoing clinical applications","volume":"6","author":"Derer","year":"2015","journal-title":"Front Immunol."},{"key":"2025100106250821000_66.10.1522.13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107322"},{"key":"2025100106250821000_66.10.1522.14","first-page":"4497","article-title":"In silico study on radiobiological efficacy of Ac-225 and Lu-177 for PSMA-guided radiotherapy","volume":"2021","author":"Birindelli","year":"2021","journal-title":"Annu Int Conf IEEE Eng Med Biol Soc."},{"key":"2025100106250821000_66.10.1522.15","doi-asserted-by":"crossref","first-page":"e202","DOI":"10.1097\/RLU.0000000000005640","article-title":"Ac-PSMA-617 augmentation after insufficient response under Lu-PSMA-617 radioligand therapy in mCRPC: evaluation of outcome and safety from a prospective registry (REALITY study)","volume":"50","author":"Rosar","year":"2025","journal-title":"Clin Nucl Med."},{"key":"2025100106250821000_66.10.1522.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.11.013"},{"key":"2025100106250821000_66.10.1522.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2016.08.052"},{"key":"2025100106250821000_66.10.1522.18","doi-asserted-by":"crossref","first-page":"6913","DOI":"10.7150\/thno.100555","article-title":"Immunological facets of prostate cancer and the potential of immune checkpoint inhibition in disease management","volume":"14","author":"Hansen","year":"2024","journal-title":"Theranostics."},{"key":"2025100106250821000_66.10.1522.19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003466"},{"key":"2025100106250821000_66.10.1522.20","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30407-3"},{"key":"2025100106250821000_66.10.1522.21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1712126"},{"key":"2025100106250821000_66.10.1522.22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.69.1584"},{"key":"2025100106250821000_66.10.1522.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.07.032"},{"key":"2025100106250821000_66.10.1522.24","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.3389\/fonc.2020.01381","article-title":"Phase II study of ipilimumab in men with metastatic prostate cancer with an incomplete response to androgen deprivation therapy","volume":"10","author":"Graff","year":"2020","journal-title":"Front Oncol."},{"key":"2025100106250821000_66.10.1522.25","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.7609"},{"key":"2025100106250821000_66.10.1522.26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200690"},{"key":"2025100106250821000_66.10.1522.27","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01638"},{"key":"2025100106250821000_66.10.1522.28","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-0327"},{"key":"2025100106250821000_66.10.1522.29","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30445-9"},{"key":"2025100106250821000_66.10.1522.30","doi-asserted-by":"crossref","first-page":"e225394","DOI":"10.1001\/jamanetworkopen.2022.5394","article-title":"Comparative effectiveness of immune checkpoint inhibitors vs chemotherapy by tumor mutational burden in metastatic castration-resistant prostate cancer","volume":"5","author":"Graf","year":"2022","journal-title":"JAMA Netw Open."},{"key":"2025100106250821000_66.10.1522.31","doi-asserted-by":"publisher","DOI":"10.1038\/nature09339"},{"key":"2025100106250821000_66.10.1522.32","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2008.271"},{"key":"2025100106250821000_66.10.1522.33","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-021-01084-0"},{"key":"2025100106250821000_66.10.1522.34","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s40880-017-0198-3","article-title":"Immune mediators in the tumor microenvironment of prostate cancer","volume":"36","author":"Dai","year":"2017","journal-title":"Chin J Cancer."},{"key":"2025100106250821000_66.10.1522.35","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2013.05.029"},{"key":"2025100106250821000_66.10.1522.36","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.636568"},{"key":"2025100106250821000_66.10.1522.37","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.265391"},{"key":"2025100106250821000_66.10.1522.38","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abb3631"},{"key":"2025100106250821000_66.10.1522.39","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.115.171397"},{"key":"2025100106250821000_66.10.1522.40","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-032712-100008"},{"key":"2025100106250821000_66.10.1522.41","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2014.10.017"},{"key":"2025100106250821000_66.10.1522.42","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20052494"},{"key":"2025100106250821000_66.10.1522.43","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-1673"},{"key":"2025100106250821000_66.10.1522.44","doi-asserted-by":"publisher","DOI":"10.1172\/JCI67313"},{"key":"2025100106250821000_66.10.1522.45","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2017.04.014"},{"key":"2025100106250821000_66.10.1522.46","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2010.09.034"},{"key":"2025100106250821000_66.10.1522.47","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-2982"},{"key":"2025100106250821000_66.10.1522.48","doi-asserted-by":"crossref","unstructured":"Potluri HK Ferreira CA Grudzinski J . Antitumor efficacy of 90Y-NM600 targeted radionuclide therapy and PD-1 blockade is limited by regulatory T cells in murine prostate tumors. J Immunother Cancer. 2022;10:e005060.","DOI":"10.1136\/jitc-2022-005060"},{"key":"2025100106250821000_66.10.1522.49","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.246041"},{"key":"2025100106250821000_66.10.1522.50","doi-asserted-by":"crossref","unstructured":"Sun J Yang JT Guo JK . Dual-targeted alpha therapy mitigates prostate cancer and boosts immune checkpoint blockade therapy. J Control Release. 2025;382:113686.","DOI":"10.1016\/j.jconrel.2025.113686"},{"key":"2025100106250821000_66.10.1522.51","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.249029"},{"key":"2025100106250821000_66.10.1522.52","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/S1470-2045(23)00451-5","article-title":"Single-dose 177Lu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: an open-label, dose-expansion, phase 1 trial","volume":"24","author":"Aggarwal","year":"2023","journal-title":"Lancet Oncol."},{"key":"2025100106250821000_66.10.1522.53","doi-asserted-by":"crossref","first-page":"abstract 5017","DOI":"10.1200\/JCO.2022.40.16_suppl.5017","article-title":"PRINCE: phase I trial of Lu-PSMA-617 in combination with pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC) [abstract]","volume":"40(suppl)","author":"Sandhu","year":"2022","journal-title":"J Clin Oncol."},{"key":"2025100106250821000_66.10.1522.54","doi-asserted-by":"crossref","first-page":"abstract 5005","DOI":"10.1200\/JCO.2023.41.16_suppl.5005","article-title":"LuPARP: phase 1 trial of 177Lu-PSMA-617 and olaparib in patients with metastatic castration resistant prostate cancer (mCRPC) [abstract]","volume":"41(suppl)","author":"Sandhu","year":"2023","journal-title":"J Clin Oncol."},{"key":"2025100106250821000_66.10.1522.55","doi-asserted-by":"crossref","first-page":"114225","DOI":"10.1016\/j.ejca.2024.114225","article-title":"Empowering effective biomarker-driven precision oncology: a call to action","volume":"209","author":"Lawler","year":"2024","journal-title":"Eur J Cancer."},{"key":"2025100106250821000_66.10.1522.56","doi-asserted-by":"crossref","first-page":"210","DOI":"10.3390\/cancers13020210","article-title":"The functional crosstalk between myeloid-derived suppressor cells and regulatory T cells within the immunosuppressive tumor microenvironment","volume":"13","author":"Haist","year":"2021","journal-title":"Cancers (Basel)."},{"key":"2025100106250821000_66.10.1522.57","doi-asserted-by":"crossref","first-page":"1070497","DOI":"10.3389\/fmed.2022.1070497","article-title":"Commercial and business aspects of alpha radioligand therapeutics","volume":"9","author":"Ostuni","year":"2022","journal-title":"Front Med (Lausanne)."},{"key":"2025100106250821000_66.10.1522.58","doi-asserted-by":"crossref","first-page":"281","DOI":"10.3892\/ol.2023.13867","article-title":"Combination of CAR-T cell therapy and radiotherapy: opportunities and challenges in solid tumors (review)","volume":"26","author":"Zhong","year":"2023","journal-title":"Oncol Lett."}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.125.270317","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T13:25:20Z","timestamp":1759325120000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.125.270317"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,28]]},"references-count":58,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10,1]]},"published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.2967\/jnumed.125.270317"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.125.270317","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,28]]}}}